# A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis

> **NCT00885196** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 336 (actual)

## Conditions studied

- Moderate and Severe Plaque Psoriasis

## Interventions

- **DRUG:** Placebo
- **DRUG:** AEB071

## Key facts

- **NCT ID:** NCT00885196
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2011-08
- **Final completion:** —
- **Target enrollment:** 336 (ACTUAL)
- **Last updated:** 2020-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00885196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00885196, "A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00885196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*